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Abstract 
Although the fibroblast growth factor (FGF) signaling axis plays important roles in cell survival, 
proliferation, and differentiation, the molecular mechanism underlying how the FGF elicits 
these diverse regulatory signals is not well understood. By using the Frs2 null mouse em-
bryonic fibroblast (MEF) in conjunction with inhibitors to multiple signaling pathways, here we 
report  that  the  FGF  signaling  axis  activates  mTOR  via  the  FGF  receptor  substrate  2 
(FRS2)-mediated PI3K/Akt pathway, and suppresses autophagy activity in MEFs. In addition, 
the PI3K/Akt pathway regulated mTOR is crucial for the FGF signaling axis to suppress au-
tophagy in MEFs. Since autophagy has been proposed to play important roles in cell survival, 
proliferation, and differentiation, the findings suggest a novel mechanism for the FGF signaling 
axis to transmit regulatory signals to downstream effectors. 
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Introduction 
The FGF family consists of 18 receptor-binding 
members that regulate a broad spectrum of cellular 
activities (1). The FGF elicits its regulatory signals via 
activating the FGFR tyrosine kinases encoded by four 
highly  homologous  genes.  FRS2,  also  called  SNT1 
for Suc13-associating neurotropic factor target 1, is a 
broadly expressed membrane-anchored adaptor pro-
tein that is required for the FGF to activate the MAP 
and PI3 kinase pathways, the two major pathways in 
the FGF signaling cascade (2-4). The FRS2 family has 
two highly homologous members, FRS2 and FRS2β. 
Frs2 is broadly expressed in adult and fetal tissues, 
whereas  Frs2β  is  more  restrictively  expressed  (5-7). 
Frs2 null mouse embryos die between embryonic (E) 
7.0-7.5 days (5). Although FRS2β can compensate for 
the loss of FRS2 with respect to MAPK activation in 
mouse  embryonic  fibroblast  (MEF)  cells  (8),  recent 
reports  demonstrate  that  FRS2  and  FRS2β  do  not 
always mediate the same signals (9-12).  
FRS2  and  FRS2β  share  similar  structure  do-
mains,  which  include  the  N-terminal  myristylation 
site  that  anchors  FRS2  to  the  cell  membrane,  the 
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phosphotyrosine-binding (PTB) domain required for 
binding  to  the  FGFR,  and  the  C-terminal  sequence 
that contains multiple tyrosine and serine/threonine 
phosphorylation sites. The PTB-binding domain of the 
FGFR  does  not  include  a  phosphorylated  tyrosine 
residue, which is different from the PTB-binding sites 
of other growth factor receptors (13). The PTB domain 
of  FRS2  also  binds  Cks1,  a  molecule  that  triggers 
degradation  of  cell  cycle  regulatory  protein  p27kip1 
during the G1/S transition in the cell cycle (14). Alt-
hough not essential (15), a VT (valine-threonine) motif 
encoded by alternatively spliced sequences in the in-
tracellular  juxtamembrane  domain  of  FGFR1  and 
FGFR2 is important for association with the PTB do-
main (3,13,16-18). Interestingly, the binding of FGFR1 
to FRS2, but not FRS2β, is enhanced by receptor au-
tophosphorylation  (15).  FRS2  has  six  tyrosine 
phosphorylation sites. Among them, Tyr196, Tyr306, 
Tyr349, and Tyr392 are Grb2-binding sites that have 
been shown to be important for transmitting the sig-
nals to the PI3K/Akt pathway. Tyr436 and Tyr471 are 
Shp2-binding sites that have been shown important 
for transmitting the signals to the MAP kinase path-
way  (19-21).  Mice  expressing  a  FRS2  mutant  that 
lacks the Shp2-binding sites exhibit severe develop-
mental defects; those that lack the Grb2-binding sites 
have less severe defects (19,22). FGF stimulation also 
causes  phosphorylations  on  multiple  ser-
ine/threonine  residues  of  FRS2,  which  provides  a 
negative feedback for the FGF signaling activity (23). 
FRS2  phosphorylation  appears  to  be  FGFR  iso-
form-specific,  which  may  result  in  differential  re-
cruitments  of downstream signaling  molecules and, 
thus, contribute to signaling specificity of the FGFR 
(24,25).  We  reported  previously  that  the  four 
Grb2-binding, but not the two Shp2-binding sites, are 
essential for FGFR1 to activate the FGF-inducible re-
sponse element (FiRE) of the mouse syndecan 1 gene 
(15),  which  is  an  enhancer  required  for  the  FGF  to 
promote syndecan 1 expression and has been widely 
used  as  a  reporter  for  the  FGF  signaling  pathway 
(15,24,26).  
Autophagy  is  a  lysosomal-mediated 
“self-digest”  process  for  degrading  and  recycling 
various cellular constituents, such as long-lived pro-
teins and entire organelles. Autophagy initiates with 
the formation of autophagosomes in which the isola-
tion  membrane  engulfs  cellular  constituents  (27). 
Autophagosomes then fuse with lysosomes to form 
autolysosomes  where  the  contents  are  degraded  by 
acidic lysosomal hydrolases. As a self-digestion sys-
tem, autophagy may influence cell survival, prolifer-
ation, and differentiation by accelerating turnover of 
old protein or organelles (28). However, whether au-
tophagy can be regulated by the FGF signaling axis is 
currently unknown.  
Here,  we  show  that  FRS2  is  required  for  the 
FGF signaling axis to activate the mTOR pathway and 
to suppress the autophagy activity in MEFs. Ablation 
of Frs2, as well as inhibition of FGFR or PI3K, but not 
ERK, kinase activity suppressed FGF to activate the 
mTOR pathway and to inhibit autophagy. Thus, the 
results,  for  the  first  time,  demonstrate  that  the 
FRS2-mediated mTOR pathway is required for the 
FGF signaling axis to regulate autophagy, and suggest 
a new mechanism by which the FGF elicits its regu-
latory signals.  
Materials and Methods 
Animals.  All animals were housed in the Pro-
gram for Animal Resources of the Institute of Biosci-
ences  and  Technology,  and  handled  in  accordance 
with the principles and procedures of the Guide for the 
Care and Use of Laboratory Animals.  All  experimental 
procedures were approved by the Institutional Ani-
mal  Care  and  Use  Committee.  The  mice  carrying 
Frs2flox were bred and genotyped as described (29). 
The embryos were harvested at embryonic day 14.5 
for  establishing  MEF  cultures  as  described  (15). 
Briefly, E14.5 embryos carrying homozygous Frs2flox 
were  minced  in  3  ml  ice-cold  0.25%  trypsin-EDTA 
solution (Sigma-Aldrich, St. Louis, MO), incubated at 
4 ºC overnight, and then 37 ºC for 30 minutes in the 
same solution. The isolated cells were propagated at a 
ratio of 1:3 in 6-well plates and maintained in 5% fetal 
bovine  serum/DMEM  until  being  used.  The  MEFs 
were  then  immortalized  by  transfection  with 
pRSV-TAg plasmid that carried the SV40 T antigens. 
Ad5-CMV-Cre-GFP and Ad5-CMV-GFP viruses from 
the Center for Cell and Gene Therapy (Houston, TX) 
were used to delete the floxed fragment.  
Transfections. Overnight cultured MEFs (1X105 
cells in 6-well plates) were transfected with 5 µg of the 
indicated  FRS2  mutants  in  pcDNAzeo  plasmids 
(Invitrogen  Corporation,  La  Jolla,  CA)  and  5  µl 
Lipofectamine (Invitrogen Corporation). Inhibitor for 
ERK1/2 kinase (SL327) was from BioSource Int., Inc. 
(Camarillo, CA), and PI3K (LY294002) was from Cell 
Signaling (Beverly, MA). Bafilomycin A1 was from LC 
Laboratories (Woburn MA). The cells were incubated 
at 37 ºC for 24 hours, and the culture media were then 
changed to a serum-free DMEM containing 10 µg/ml 
heparin for serum starvation. After incubation at 37 ºC 
for 12 hours, the cells were stimulated with FGF2 at 
the  indicated  concentrations  for  the  indicated  times 
before being lysed with 200 µl RIPA buffer containing 




ma-Aldrich, Inc. St Louis, MO) for Western blot anal-
yses.  
Western blot. The cell lysates equivalent to 50 µg 
total  proteins  were  separated  on  SDS-PAGEs  and 
blotted onto PVDF membranes for Western analyses 
with the indicated antibodies. The sources and dilu-
tion  of  the  antibodies  are:  phosphorylated  FRS2 
Tyr196  (1:1000),  phosphorylated  ERK1/2  (1:1000), 
phosphorylated Akt Thr308 (1:1000), phosphorylated 
Akt Ser473 (1:1000), and phosphorylated S6K1 Thr389 
(1:1000)  from  Cell  Signaling  Technology  Inc.  (Dan-
vers, MA); human LC3 (1:500) from Novus Biologi-
cals, LLC (Littleton, CO); and β-actin (1: 5000) from 
Santa Cruz Biotechnology, Inc., (Santa Cruz, CA). The 
specifically bound primary antibodies were detected 
with the horseradish peroxidase conjugated second-
ary  antibodies  and  visualized  with  the  ECL-plus 
Chemoluminescent reagents. The immunoblot results 
were developed on X-ray film.  
Results and Discussion 
FGF2 activates the mTOR pathway in a 
time-dependent manner.  
We previously reported that the MEF cells de-
rived from Frs2 floxed embryos are able to respond 
to  FGF  signals  (15).  Since  the  FRS2-mediated 
PI3K/Akt  pathway  is  an  upstream  regulator  of  the 
mTOR pathway, we investigated whether FGF acti-
vated mTOR. MEF cells were treated with FGF2 at the 
final concentration of 5 ng/ml, and lysed at various 
time points. Activation of the FGF signaling axis and 
mTOR  pathway  was  analyzed  by  Western  blot. 
Treating with FGF2 induced FRS2 phosphorylation 
within  5  minutes.  The  phosphorylation  was  then 
gradually  reduced  (Fig.  1).  Consistently,  Akt  and 
Erk1/2, the major downstream molecules of the FGF 
signaling  axis,  were  also  strongly  phosphorylated 
within 5 minutes, which were then gradually reduced. 
S6K1, the major substrate of the mTOR C1 complex, 
was  also  strongly  phosphorylated,  although  the 
phosphorylation  was  slightly  delayed.  Consistently, 
phosphorylation of mTOR S2448, an S6K1 phosphor-
ylation  site  (30),  was  increased  at  a  lagging  mode. 
Together,  the  results  demonstrate  that  the  FGF  sig-
naling axis induces activation of the mTOR pathway.  
FRS2 is required for FGF2 to activate the 
mTOR pathway. 
FRS2 is an adaptor protein in the FGF signaling 
pathway, which recruits multiple downstream path-
ways, including the ERK1/2 and PI3K/Akt pathways, 
to  the  FGFR  kinase.  To  investigate  whether  FRS2 
was required for FGF2 to activate the mTOR pathway, 
MEFs bearing homozygous Frs2 floxed alleles were 
treated with adenovirus-Cre/GFP to delete the floxed 
fragment. The infected cells were isolated with a flu-
orescence-activated cell sorter. PCR analyses showed 
that no floxed allele  was  detected (Fig. 2A). Unlike 
MEFs  bearing  floxed  Frs2  alleles  that  exhibited 
strong activation of ERK1/2, Akt, and S6K1 by FGF2, 
MEFs bearing Frs2 null alleles failed to respond to 
FGF2 with respect to ERK1/2, Akt, and S6K1 phos-
phorylation  (Fig.  2B).  The  weak  activation  of  ERK 
activation  in  Frs2  null  MEFs  were  likely  due  to 
FRS2-independent pathways. The results indicated 
that FRS2 was required for the FGF signaling axis to 
activate the mTOR pathway. Interestingly, the back-
ground phosphorylation of Akt S473, an mTOR-rictor 
phosphorylation site (31), was significantly increased 
in Frs2 null MEF. This is not surprising since FRS2 
has been shown to play important roles in cell sig-
naling feedback regulation (32). To confirm that the 
results  were  not  associated  with  the  cloning  proce-
dure, primary MEFs were isolated from Frs2 floxed 
embryos and infected either with adenovirus-GFP or 
adenovirus-Cre/GFP to repeat the experiments. The 
results demonstrated that ablation of the Frs2 alleles 
significantly  impaired  activation  of  Akt,  ERK,  and 
mTOR  by  FGF2  (Fig.  2C),  which  confirmed  that 
FRS2 was required for FGF2 to activate the mTOR 
pathway.  In  addition  to  the  FRS2-independent 
pathway, incomplete disruption of Frs2 in primary 
MEFs  might  also  contribute  to  compromised  phos-
phorylation of ERK1/2 induced by FGF2.  
 
Fig.  1.  FGF2  activates  the  mTOR  pathway  in  a 
time-dependent  manner.  Wildtype  mouse  embryonic  fi-
broblasts (MEFs) treated with 5 ng/ml FGF2 were lysed and 
immunoblotted with the indicated antibodies. β-actin was 





Fig. 2. FRS2 is required for FGF2 to activate the mTOR 
pathway. A. Total RNA was extracted from Frs2 null or 
wildtype  MEF  for  RT-PCR  analysis  of  Frs2  expression. 
GAPDH  was  used  as  a  loading  control  B.  Immortalized 
MEFs bearing Frs2 floxed (Flox) or null (KO) alleles were 
treated  with  FGF2  (5  ng/ml)  for  10  minutes,  and  the 
phosphorylated  proteins  were  immunoblotted  with  the 
indicated antibodies. C. MEFs bearing Frs2 floxed alleles 
infected with adenovirus bearing GFP (GFP) or Cre/GFP 
cDNAs were incubated with FGF2 as in A. The phosphor-
ylated  proteins  were  immunoblotted  with  the  indicated 
antibodies.  
FGF2 activates the mTOR pathway via the 
PI3K/Akt pathway. 
FRS2  has  6  tyrosine  phosphorylation  sites  of 
which  4  are  Grab2  binding  that  are  important  for 
PI3K/Akt activation and 2 are Shp2 binding that are 
important  for  MAP  kinase  activation  (19).  Both 
PI3K/Akt and MAP kinase pathways can be linked to 
the mTOR pathway (33). To determine which path-
way is required for FGF2 to activate mTOR in MEFs, 
inhibitor  specific  for  either  PI3K  or  MEK1/2  was 
added to block the PI3K/Akt or MAP kinase path-
way,  respectively.  Inhibition  of  PI3K,  but  not 
MEK1/2, abolished the phosphorylation of S6K1, in-
dicating  that  only  the  PI3K/Akt  pathway  was  re-
quired for FGF2 to activate the mTOR pathway (Fig. 
3). Interestingly, inhibition of the MAP kinase path-
way  significantly  increased  the  phosphorylation  of 
Akt  T308  and  S473,  which  were  catalyzed  by  the 
PI3K/PDPK1 (phosphoinositide dependent kinase 1) 
and  mTOR  C2,  respectively.  Thus,  the  results  sug-
gested  that  inhibition  of  the  MAP  kinase  pathway 
sustained  or  promoted  activation  of  the  Akt-mTOR 
signaling axis. The results are in line with the reports 
that sustained activation of the MAP kinase provides 






Fig. 3. FGF2 activates the mTOR pathway via the PI3K/Akt 
pathway. A. Immortalized MEFs bearing Frs2 floxed alleles 
were treated with 5 ng/ml FGF2 in the presence or absence 
of the PI3K (10 nM, LY294002) or MEK (10 nM, SL327) 
inhibitors as indicated. The phosphorylated proteins were 




FRS2 is required for FGF2 to inhibit autoph-
agy through the mTOR pathway. 
The mTOR pathway is a major signaling path-
way  that  inhibits  autophagy  (34).  To  investigate 
whether FGF signaling regulated autophagy, we then 
assessed the influence of FGF2 on LC3 II abundance. 
LC3, also called microtubule associated light chain 3, 
is a broadly used autophagy indicator. The full-length 
ProLC3 is processed to its cytosolic form, LC3 I, which 
is activated by conversion to its lipidated form, LC3 II. 
The  lipidated  LC3  II  is  translocated  to  preautopha-
gosomes  and  autophagosomes,  which  are  then  de-
graded  after  fusing  with  lysosomes.  Thus,  the  in-
creased  abundance  of  LC3  II  reflects  enhanced  au-
tophagic activity or reduced autophagosome turnover 
(35,36). To determine whether the FGF signaling axis 
regulated  autophagy,  the  MEFs  with  either  Frs2 
floxed or null alleles were treated with FGF2, and the 
abundance  of  LC3  was  assessed  by  Western  blot. 
Treating the Frs2 floxed MEFs with FGF2 enhanced 
S6K1 phosphorylation and reduced the abundance of 
the  LC3  II  isoform,  suggesting  that  FGF2  regulated 
autophagy, likely through the mTOR pathway. Con-
sistent  with  the  result  that  FGF2  treatment  did  not 
induce S6K1 phosphorylation in Frs2 null MEFs (Fig. 
2B),  FGF2  treatment  also  did  not  reduce  LC3  II 
abundance in Frs2  null  MEFs (Fig. 4A), indicating 
that FGF2 regulated the autophagy activity through 
FRS2-mediated pathway(s).  
As the abundance of the LC3 II isoform was dy-
namically  controlled,  the  variation  of  LC3  II  abun-
dance alone may reflect either an inhibition of LC3 I to 
LC3 II conversion or an activation of LC3 II turnover. 
ATG1 and ATG13 are substrates of the mTOR C1 ki-
nase  that  is  activated  by  the  PI3K/Akt  pathway. 
Phosphorylation of ATG1 and ATG13 by mTOR C1 
changes the conformation of the ATG1 complex to an 
“open” conformation, resulting in suppression of au-
tophagy (34). As S6K1 is a substrate of the mTOR C1 
kinase, which is often used as readout for mTOR C1 
activity, the data of enhanced S6K1 phosphorylation 
in FGF2 treated MEFs inclines toward the possibility 
that  autophagic  activity  is  repressed  by  increased 
mTOR  C1  activity.  To  clarify  how  FGF2  regulated 
autophagy, the MEFs were treated with bafilomycin 
A1 to suppress the fusion between autophagosomes 
and lysosomes (37). Although blocking the degrada-
tion of LC3 II by suppression of fusions between au-
tophagosomes  and  lysosomes  increased  the  abun-
dance of LC3 II either in the presence or absence of 
FGF2, treating the cells with FGF2 still significantly 
reduced the abundance of the LC3 II isoform, indi-
cating less LC3 II formation (Fig. 4B). Therefore, the 
results indicate FGF2 suppresses LC3 I to LC3 II con-
version, and thus, the autophagy initiation in cells. To 
determine whether the mTOR pathway was required 
for  FGF2  to  suppress  autophagy,  rapamycin,  an 
mTOR C1 inhibitor, was added to the MEF cultures. 
Treating with rapamycin suppressed the phosphory-
lation  of  S6K1  and  increased  the  abundance  of  the 
LC3 II in FGF2 treated MEFs (Fig. 4C), although it did 
not affect Akt and Erk1/2 phosphorylation (data not 
shown). Separate experiments revealed that treating 
with rapamycin alone did not increase LC3 II abun-
dance in MEFs (Fig. 4C).  
 
Fig. 4. FRS2 is required for FGF2 to inhibit autophagy via 
the mTOR pathway. A. Overnight cultures of immortalized 
MEFs bearing Frs2 floxed (Flox) or null (KO) alleles were 
cultured in a serum-free condition in the presence or ab-
sence of 5 ng/ml FGF2 for 2 hours, and the abundance of 
phosphorylated  S6K1  and  LC3  II  isoforms  were  im-
munoblotted as indicated. B&C. Immortalized MEFs bearing 
Frs2 floxed alleles were treated with FGF2 in the presence 
or absence of bafilomycin A1 (B) or rapamycin (C), and the 
abundance of phosphorylated S6K1 and LC3 II isoforms 




The results suggest that activation of mTOR C1 
is required for FGF2 to suppress the autophagy activ-
ity. Further experiments with other autophagy mark-
ers, including expression of P62, ATG5, ATG12, etc., 
will  be  carried  out  to  unravel  detailed  molecular 
mechanisms underlying this regulation.  
Two Grb2 binding sites of FRS2, Y349 and 
Y392, are required for FGF signals to suppress 
autophagy. 
Reinstatement of full length FRS2 expression in 
Frs2 null MEFs by transfection restored regulation of 
FGF2 on the autophagy activity (Fig. 5). To determine 
whether  the  Grb2-  or  Shp2-binding  sites  were  re-
quired for regulating autophagy, mutants lacking the 
four Grb2- or two Shp2-binding sites were expressed 
in  Frs2  null  MEFs  as  described  (15).  To  better 
demonstrate the difference in LC3 II abundance, only 
lightly exposed films were shown. Therefore, LC3 I 
bands  in  this  figure  are  too  weak  to  be  seen.  Con-
sistent  with  the  chemical  inhibition  experiments 
demonstrating  that  the  PI3K/Akt,  but  not  ERK, 
pathway was required for FGF2 to suppress autoph-
agy,  expression  of  the  FRS2  mutant  lacking  the 
Grb2-binding sites (Y196, Y306, Y349, and Y392) failed 
to restore the activity, whereas expression of FRS2 
lacking  the  Shp2  binding  sites  (Y436  and  Y471)  re-
stored the response to FGF2 with respect to autoph-
agy inhibition. The results again demonstrate that the 
FGF signaling pathway regulates autophagy through 
the Grb2-mediated PI3K/Akt pathway. There are four 
Grb2-binding sites on FRS2. To further investigate 
which  Grb2-binding  phosphorylation  sites  were  re-
quired for FRS2 to mediate the autophagy regulation 
signals,  mutant  FRS2  carrying  an  individual 
Grb2-binding site mutation were expressed in Frs2 
null MEFs. Expression of mutants with a substitution 
of either Y196 or Y306 with phenylalanine rescued the 
FGF  activity  to  inhibit  autophagy  activity,  whereas 
expression of the mutant with a substitution of either 
Y349 or Y392 with phenylalanine failed to rescue such 
defects  (Fig.  5).  The  results  indicate  that  Y349  and 
Y392, but not Y196 and Y306, are required for the FGF 
to  suppress  autophagy,  and  imply  that  each 
Grb2-binding site may mediate a subset of FGF sig-
nals. Activation of PI3-kinase is mediated by assembly 
of Gab1 to the Grb2/FRS2 complex, which enables 
tyrosine phosphorylation of Gab1 by FGFR to gener-
ate  binding  sites  for  p85,  the  regulatory  subunit  of 
PI3-kinase, thus resulting in recruitment and activa-
tion  of  the  PI3-kinase  (38).  Although  all  four 
Grb2-binding sites are involved in activation  of the 
PI3K/Akt  pathway  in  3T3  cells  (2),  only  two 
Grb2-binding sites are involved in autophagy regula-
tion in MEFs. The molecular mechanism underlying 
this  discrepancy  remains  elusive  and  needs  to  be 
studied in the future.  
The  results  suggest  that  the  autopha-
gy-suppressing signals of the FGF signaling axis are 
different  from  the  FiRE-activating  signals  that  are 
mediated by the four Grb2-binding sites additively, 
since substitution of each Grb2-binding site only par-
tially reduces FiRE activation activity (15). The FiRE 
consists  of  a  170-bp  array  of  five  DNA  motifs  that 
bind  two  FGF-inducible  Fos-Jun  heterodimers,  one 
inducible  AP-2-related  protein,  one  constitutively 
expressed upstream stimulatory factor, and one con-
stitutive  46-kDa  transcription  factor.  It  has  been 
shown that FiRE is selectively activated by the FGF, 
but  not  by  other  tyrosine  kinase  receptor-activating 
growth  factors  (26).  Furthermore,  the  FGF  activates 
FiRE independent of its mitogenic activity in prostate 
cancer cells (24). Here we showed that the signals of 
FGF to regulate the mTOR/autophagy pathway was 
different from those for FiRE activation, and further 
demonstrate mechanistic diversity of the FGF signal-
ing axis.  
Although  widely used, LC3 lipidation is  not a 
perfect marker for autophagy (39). Furthermore, it has 
been reported that the LC3 antibody exhibits different 
detection sensitivities toward LC3 I and LC3 II (40). 
Therefore,  future  efforts  to  monitor  expression  of 
other  autophagic  markers,  such  as  P62,  ATG5,  and 
ATG12, etc., will be needed to confirm the findings 
and to elucidate the molecular mechanism underlying 
how  FGF  signaling  regulates  autophagic  activity. 
Autophagy  is  a  major  cellular  pathway  to  degrade 
bulky  subcellular  organelles  and  macromolecules, 
and plays important roles in development, metabo-
lism, tumorigenesis, and diseases (41). However, how 
autophagy contributes to development is not under-
stood, although it has been proposed that autophagy 
may influence cell differentiation either by impairing 
new protein or organelle formation or by accelerating 
turnover of old proteins or organelles. In this study, 
we provided the first in vitro evidence that autophagy 
can be negatively regulated by the FGF signaling axis. 
Recently, we also discovered that the FGF regulates 
cardiac progenitor cell and cardiomyocyte differenti-
ation  via  controlling  the  mTOR  pathway-regulated 
autophagy,  and  that  the  FRS2-mediated  pathways 
are required for the FGF to suppress premature dif-
ferentiation  of  heart  progenitor  cells.  Inhibition  of 
autophagic  activity  suppresses  cardiomyocyte  dif-
ferentiation both in the second heart field progenitors 






Fig. 5. Two Grb2 binding sites, Y349 and Y392, are required for FRS2 to mediate FGF signals for regulating autophagy. 
MEFs bearing Frs2 null alleles transfected with cDNAs encoding the indicated FRS2 mutants were incubated in the 
presence or absence of FGF2 as indicated, and the abundance of LC3 II isoforms was analyzed by Western blot. Arrows 
indicate LC3 II isoform. 6F, FRS2 mutant that has mutations on all six tyrosine phosphorylation sites; 2F, FRS2 mutant that 
has mutations on the two Shp2-binding tyrosine phosphorylation sites, Y436 and Y471; 4F, FRS2 mutant that has mutations 
on the four Grb2-binding tyrosine phosphorylation sites, Y196, Y306, Y349, and Y392; 196F, 306F, 349F, and 392F, FRS2 
mutants that have a single mutation on the indicated tyrosine phosphorylation sites. 
 
 
In summary, the FGF signaling axis activated the 
mTOR kinase and repressed autophagy by activating 
the FRS2-mediated PI3K/Akt pathway. Suppression 
of mTOR activation abolished the repression activity 
of FGF2 on autophagy, indicating that FGF regulated 
autophagy via the mTOR  pathway. This is the first 
report that the FGF signaling axis plays a crucial role 
in autophagy regulation, thus, sheding new light on 
cell signaling mechanisms. 
Abbreviations  
FGF:  fibroblast  growth  factor;  FGFR:  FGF  re-
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